Overview
Exome is a Delaware limited liability company with its principal place of business in New York.
Exome was formed in 2018 and commenced investment advisory operations in June 2019. Exome
was founded by its principal owner Samuel D. Isaly, who is the Managing Partner. Mr. Isaly owns
his interest in Exome directly through a limited liability company.
Exome provides discretionary investment advisory services to private funds: Emerging Markets
Healthcare Partners LLC, a Delaware limited liability company, and Worldwide Healthcare
Partners LLC, a Delaware limited liability company (collectively with Emerging Markets
Healthcare Partners LLC the “Onshore Funds”), as well as Emerging Markets Healthcare Partners
International Ltd, a Cayman Islands exempted company, and Worldwide Healthcare Partners
International Ltd, a Cayman Islands exempted company (the “Offshore Funds” and collectively
with the Onshore Funds the “Fund” or “Funds”). Exome Asset GP LLC (the “Managing
Member”), which is a related entity of Exome, serves as the Managing Member to the Onshore
Funds. In addition, Exome also provides discretionary investment sub-advisory services to a
pooled investment vehicle (“Sub-Advised Fund”). Exome has in place an investment
management agreement with each of the private funds, as
well as the Sub-Advised Funds.
Exome is responsible for determining the specific securities and other investments to be bought
and sold and arranging the execution of all purchase and sale orders on behalf of the Funds.
Exome’s advisory services are provided to Funds pursuant to the terms of the Funds’ private
placement memorandum, operating agreement, limited partnership agreement, sub-advisory
agreement, and/or investment management agreement, as applicable (collectively, the “Governing
Documents”) and based on the specific investment objectives and strategies as disclosed therein.
Please refer to ITEM 8 methods of analysis, investment strategies, and risks of loss.
Exome generally does not permit investors in the Funds to impose limitations on the investment
activities described in the offering documents for the Exome Funds. Under certain circumstances,
Exome will contract with a client to adhere to the limited risk and/or operating guidelines imposed
by the client. Exome negotiates such arrangements on a case-by-case basis.
Exome does not participate in wrap-fee programs.
As of December 31, 2023, Exome managed approximately $181,836,994 of client regulatory
assets on a discretionary basis. Exome does not currently manage any client assets on a non-
discretionary basis.